BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsFDA / regulatory

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value

Related news

TARSTarsus Pharmaceuticals2026-09-04 12:39 EST

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

HROWHarrow, Inc.2026-10-05 11:00 EST

Harrow Closes Acquisition of TYRVAYA®

RHHBYRoche Holdings AG2026-10-16 05:00 EST

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

RHHBYRoche Holdings AG2026-10-09 05:00 EST

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

OTLKOutlook2026-08-14 11:15 EST

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

OTLKOutlook2026-07-24 18:40 EST

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

OKYOOKYO Pharma2026-07-08 11:00 EST

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-11-05 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-11-03 21:05 EST

Tarsus Reports Third Quarter 2026 Financial Results

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

TARSTarsus Pharmaceuticals2026-10-28 12:30 EST

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

Stock data

Close
67.52 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States